GOSS
NASDAQ HealthcareGossamer Bio, Inc. - Common Stock
Biotechnology
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
๐ Market Data
| Price | $0.20 |
|---|---|
| Volume | 11,491,307 |
| Market Cap | 46.99M |
| Beta | 2.150 |
| RSI (14-Day) | 26.0 Oversold |
| 200-Day MA | $1.89 |
| 50-Day MA | $0.33 |
| 52-Week High | $3.87 |
| 52-Week Low | $0.16 |
| Forward P/E | -1.83 |
| Price / Book | -0.29 |
๐ฏ Investment Strategy Scores
GOSS scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ช Falling Knife (99/100) โ this strategy Contrarian plays (oversold + below moving average).
Lowest fit among scored strategies: ๐ Institutional Whale (1/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find GOSS in your text
Paste any article, transcript, or post โ the tool will extract GOSS and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-06-02.